TIDMBXP
RNS Number : 8844M
Beximco Pharmaceuticals Ltd
19 October 2016
BEXIMCO PHARMACEUTICALS LTD.
19 October, 2016
AGM Notification
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP), today announces that the 40(th) Annual
General Meeting of the Shareholders of Beximco Pharmaceuticals
Limited will be held on Saturday, the 19 November, 2016. The
meeting will take place at 10.30 a.m. at Beximco Industrial Park,
Sarabo, Kashimpur, Gazipur to transact the following business:
AGENDA
1. To receive, consider and adopt the Audited Financial
Statements of the Company for the period of 18 months ended on June
30, 2016 together with reports of the Auditors and the Directors
thereon;
2. To declare/approve 5% final Cash Dividend, 5% Stock Dividend
and 10% Cash Dividend (already paid as interim dividend) for the
period of 18 months ended on June 30, 2016;
3. To elect Directors;
4. To approve the audit fee for the period of six months-January
1, 2016 to June 30, 2016; to appoint Auditors for the year
2016-2017 and to fix their remuneration;
5. To adopt changes in Accounting year of the Company from
January-December to July-June pursuant to the provision of the
Finance Act 2015;
6. To transact any other business of the Company with the permission of the Chair.
By order of the Board,
MOHAMMAD ASAD ULLAH, FCS
Executive Director & Company Secretary
NOTES
1. The Record Date of the Company for entitlement of 5% Final
Cash dividend shall be November 1, 2016. The Shareholders whose
names will appear in the Share Register of the Company or in the
Depository Register on the record date i.e. November 1, 2016 will
be entitled to receive the 5% final cash dividend.
2. 5% Stock Dividend will be entitled by the Shareholders whose
names appeared in the Share Register of the Company or in the
Depository Register on the earlier declared record date i.e. May
12, 2016.
3. A Member entitled to attend and vote at the General Meeting
may appoint a Proxy to attend and vote in his/her stead. The Proxy
Form, duly stamped, must be deposited at the Registered Office of
the Company, not later than 48 hours before the time fixed for the
meeting.
4. Admission to the meeting room will be strictly on production
of the attendance slip sent with the Notice as well as verification
of signature of Member(s) and/or Proxy-holder(s).
5. Members are requested to update particulars of their Bank
Account, change of address (if any) and 12 digit Taxpayer's
Identification Number (E-TIN) through their respective Depository
Participant.
6. No gift or benefit in cash or kind shall be paid to the
holders of equity securities in terms of Clause (c) of the
Notification No.SEC/SRMI/2000-953/1950 dated 24 October 2000 for
attending the AGM of the Company.
For further information please visit www.beximco-pharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080
Md. Asad Ullah, FCS, Executive Director & Company
Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Sean Wyndham-Quin
Tel: +44 (0)20 3368 3551 / 3555
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma
manufactures and sells generic pharmaceutical formulation products
and active pharmaceutical ingredients. The Company also undertakes
contract manufacturing for multinational and leading global generic
pharmaceutical companies. The Company operates from a 23 acre site
in Dhaka and has manufacturing facilities for producing various
drugs in different delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, prefilled syringes,
injectables, nebulizer solutions, oral soluble films, etc. Ensuring
access to quality medicines is the powerful aspiration that
motivates over 3,500 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of the US, Australia,
Europe, Latin America and Canada, among others. The Company's
products are sold to retail outlets, medical institutions and other
pharmaceutical manufacturers in Bangladesh, in regional markets
such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and
in other markets overseas, principally in Africa, including South
Africa, Mauritius, Kenya, Ghana, Ethiopia and Nigeria; Pacific
Island; Latin and Central American countries; Middle East; Central
Asia; South East Asia, including Singapore, Malaysia, Indonesia,
Philippines and Hong Kong; Europe, including Germany, Austria and
Romania; Australia.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAUWVNRNVARAAA
(END) Dow Jones Newswires
October 19, 2016 02:00 ET (06:00 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024